Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Bruno VincenziMike TrowerAjay DuggalPamela GuglielminiPeter HarrisDavid JacksonMario E LacoutureEmiliangelo RattiGiuseppe ToniniAndrew WoodPublished in: BMJ open (2020)
EudraCT2013-002763-25.